Although considered the dominant blood supply in the early stages of some cancers, VM in GBM often acts as a resistance mechanism to anti-VEGF therapy, allowing for the neovascularisation of GBM despite anti-angiogenic treatment [13]. Here, VEGFA is linked to cancer.